Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - celecoxib 100mg;  ;   - capsule - 100 mg - active: celecoxib 100mg     excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate povidone sodium laurilsulfate - symptomatic treatment of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. for the management of acute pain and treatment of primary dysmenorrhoea in adults. the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapies have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient, and · after assessment of the individual patient's overall risks. as the cardiovascular risks of the selective cox-2 inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. patients on long-term treatment should be reviewed regularly, such as every three months, with regards to efficacy, risk factors and ongoing need for treatment.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - celecoxib 200mg;  ;   - capsule - 200 mg - active: celecoxib 200mg     excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate povidone sodium laurilsulfate - symptomatic treatment of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. for the management of acute pain and treatment of primary dysmenorrhoea in adults. the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapies have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient, and · after assessment of the individual patient's overall risks. as the cardiovascular risks of the selective cox-2 inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. patients on long-term treatment should be reviewed regularly, such as every three months, with regards to efficacy, risk factors and ongoing need for treatment.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - celecoxib 400mg;   - capsule - 400 mg - active: celecoxib 400mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate povidone sodium laurilsulfate tekprint green sb-4027 titanium dioxide - symptomatic treatment of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. for the management of acute pain and treatment of primary dysmenorrhoea in adults. the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapies have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient, and · after assessment of the individual patient's overall risks. as the cardiovascular risks of the selective cox-2 inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. patients on long-term treatment should be reviewed regularly, such as every three months, with regards to efficacy, risk factors and ongoing need for treatment.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - tigecycline 50mg (plus a 6% overage to compensate for losses during reconsitution and withdrawal);   - powder for injection - 50 mg - active: tigecycline 50mg (plus a 6% overage to compensate for losses during reconsitution and withdrawal)   excipient: lactose monohydrate - tygacil is indicated for the treatment of the following infections in adults: · complicated skin and skin structure infections, including those with methicillin-resistant staphylococcus aureus (mrsa), where there is suspected or proven resistance to, intolerance of, or there are co-morbidities preventing the use of, other available agents. · complicated intra-abdominal infections, where there is suspected or proven resistance to, intolerance of, or there are co-morbidities preventing the use of, other available agents.

Irska - angleščina - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - citalopram hydrobromide - film-coated tablet - 10 milligram(s) - selective serotonin reuptake inhibitors; citalopram

Irska - angleščina - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - citalopram hydrobromide - film-coated tablet - 20 milligram(s) - selective serotonin reuptake inhibitors; citalopram

Irska - angleščina - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - citalopram hydrobromide - film-coated tablet - 40 milligram(s) - selective serotonin reuptake inhibitors; citalopram

Irska - angleščina - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - escitalopram oxalate - film-coated tablet - 20 milligram(s) - selective serotonin reuptake inhibitors; escitalopram

Irska - angleščina - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - escitalopram oxalate - film-coated tablet - 5 milligram(s) - selective serotonin reuptake inhibitors; escitalopram

Irska - angleščina - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - escitalopram oxalate - film-coated tablet - 10 milligram(s) - selective serotonin reuptake inhibitors; escitalopram